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Copyright © 2010 JCBN Summary There is limited data about the mucosal lesions of portal hypertensive enteropathy
(PHE) detected by capsule endoscopy, and there is no scoring system to evaluate their severity.
Our aim is to create a reliable scoring system for PHE, and to explore the possible usefulness
of using transient elastograhy (TE) in that field. We compared the medical records of 31
patients with liver cirrhosis and portal hypertension with 29 control patients. We found that
the mucosal lesions compatible with PHE were significantly more common in cirrhotic
patients than in control patients (67.7% vs 6.9%, p<0.001). Cirrhotic patients with high TE
score (p = 0.018), high Child-Pugh grade, large esophageal varices (EV), portal hypertensive
gastropathy, and history of endoscopic variceal injection sclerotherapy or ligation (EIS/EVL)
were significantly associated with PHE. Using our scoring system, we found that patients with
higher TE score (p = 0.004), high Child-Pugh score (p = 0.011), larger EV (p = 0.006), and prior
EIS/EVL (p = 0.006) were significantly associated with higher PHE score. We concluded that
using our scoring system might be helpful in grading PHE severity, and TE might be a new
non-invasive method for detecting the presence and severity of PHE in cirrhotic patients.
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Introduction
Patients with liver cirrhosis exhibit portal hypertension
(PHT), which causes various pathological changes in the
entire gastrointestinal tract (from esophagus to anus) [1]. In
the recent past, the term portal hypertensive intestinal
vasculopathy has been used to explain the effects of PHT on
the entire bowel and includes portal hypertensive gastro-
pathy (PHG), enteropathy, and colonopathy [2]. Among these
pathological lesions, esophageal varices (EV), PHG, and
portal hypertensive colonopathy represent common sources
of bleeding, and they are usually diagnosed and treated by
esophagogastroduodenoscopy (EGD) and colonoscopy [2, 3].
Portal hypertensive gastropathy is a well-established
cause of bleeding in cirrhotic patients, present in up to 98%
of patients with PHT [4], and accounts for 25.8% of acute
bleeding episodes [5]. Similarly, portal hypertensive colono-
pathy has been known and described [3, 6, 7]. Although it
is found in up to 70% of patients with PHT and is more
frequent in patients with evidence of esophageal varices or
PHG [8], it seems to be a rare cause of bleeding [6, 7].
The recognized existence of PHG and portal hypertensive
colonopathy suggests that the small intestine might also
show mucosal changes related to PHT, which is called portal
hypertensive enteropathy (PHE). In fact, in 1989, Thiruven-U.M. Abdelaal et al.
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gadam and Gostout reported three patients with blood loss,
who had diffuse erythema and scattered petechia not only in
the stomach but also in the duodenum and jejunum [8].
The small intestine constitutes the largest part of the gut.
However, little is known about the endoscopic features of
the small bowel in different diseases, especially liver
cirrhosis [9]. Our limited knowledge about small intestine is
attributed to the limitations of conventional endoscopy
because only small parts of it can be examined by EGD or
colonoscopy [10]. Nowadays, completely the small intestine
is easily explored with the advent of new endoscopic
methods, such as capsule endoscopy (CE) [6, 11]. Capsule
endoscopy discovered also many diseases in small intestine
[12, 13].
FibroScan® apparatus
Transient elastography is a novel, ultrasound based tech-
nology that involves acquisition of pulse-echo ultrasound
signals to measure liver stiffness using FibroScan apparatus
[14]. In brief, the tip of an ultrasound transducer probe is
placed between ribs over the right lobe of the liver. The
probe transmits a low-amplitude (vibration and frequency)
signal to the liver, which in turn induces an elastic shear
wave that propagates through liver tissue. The pulse-echo
ultrasound allows measurement of wave velocity, expressed
in kilopascals, a measure of liver stiffness. Normal liver
stiffness is reported to be in the range of 4–6 kilopascals
(kPa) [15]. Transient elastography is associated with
attractive features beyond the fact that it is noninvasive.
Most important, it assesses a relatively large sample-across
an area of 1–2 cm of the liver, estimated to be some 100
times greater than a liver biopsy specimen is. Additionally,
transient elastography allows multiple readings to be taken
(from slightly different areas, thereby providing data on an
even larger sample). This is critical because sampling error
associated with liver biopsy [16] is likely due to the small
portion of the liver sampled [17].
Measurement of the hepatic venous pressure gradient
(HVPG) is currently considered the golden standard for the
evaluation of PHT [18]. Nevertheless, HVPG measurement
is invasive, relatively expensive, difficult, time consuming,
and available only in major centers. Many recent studies
proposed the use of liver stiffness measurement (LSM)
using TE for the detection of liver cirrhosis and the predic-
tion of its related complications, including the presence of
EV and variceal bleeding [19, 20]. Vizzutte et al. proposed
that liver stiffness measurement by using TE may represent
a non-invasive, rapid, cheap, and easy method for the predic-
tion of clinically significant (HVPG ≥10 mm Hg) and severe
portal hypertension (HVPG ≥12 mm Hg) with a cut-off
value of LSM ≥13.6 kPa and ≥17.6 kPa, respectively [21].
To our knowledge, there are limited prospective studies in
which CE was used to assess the frequency, features, and
scoring system of the mucosal lesions of PHE. In addition,
there are no prospective trials that have studied the associa-
tion between the TE score, and the presence/severity of
mucosal lesions of PHE detected by CE to declare whether
or not TE has a clinical impact in that field.
The purpose of this study was to create a reliable scoring
system for the small bowel mucosal findings of PHE in order
to evaluate its severity, and to explore the clinical impact of
using transient elastography in that field.
Materials and Methods
Patients
This is a non-randomised, controlled, prospective study of
a cohort of 31 patients with documented liver cirrhosis and
PHT. They were admitted to our hospital from June 2008 to
October 2009. Written informed consent was obtained from
all the patients after a precise explanation of the nature and
purpose of our study. The ethics committee of our hospital
approved the study.
Inclusion criteria were evidence of liver cirrhosis and
PHT. Patients with a prior history of endoscopic variceal
injection sclerotherapy (EIS) or ligation (EVL) were also
included. Exclusion criteria were the following: recent
history or current intake of medications which affect the
degree of PHT (such as diuretics and beta-blockers), and the
intestinal mucosa (such as non-steroidal anti-inflammatory
drugs), presence of renal or cardiac impairment, and patients
with enteritis from another cause, such as Crohn’s disease.
The control arm consisted of 29 patients who were
selected from our hospital’s patients with obscure gastro-
intestinal bleeding that were diagnosed as; bleeding duodenal
ulcer (two patients), colonic angioectasia (one patient),
colonic ulcer (one patient), and colonic diverticulosis (25
patients). The indication of CE was to exclude any other
bleeding points in the small intestine. All control patients
had no clinical, laboratory, and radiological evidence of liver
cirrhosis and/or PHT.
Liver cirrhosis was diagnosed by the history of chronic
liver disease, clinical features, laboratory and typical
radiological and/or histological data of liver cirrhosis. Portal
hypertension was diagnosed by the endoscopic evidence of
esophageal and/or gastric varices and/or TE score ≥13.6 kPa
[21].
Severity of liver cirrhosis was graded according to Child-
Pugh score [22]. A high Child Pugh score was considered if
it was more than grade 6.
Transient elastography
Transient elastography was performed using the FibroScan®
apparatus (Echosens, Paris, France). The operator was a
staff physician who had previously performed at least 100
determinations in patients with chronic liver disease. TheScoring System for PHE using CE
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median value of 10 successful acquisitions was kept as
representative of TE score of the patients [23].
Endoscopic findings
Esophageal and gastric varices were graded by using the
standard criteria proposed by the Japanese Society for Portal
Hypertension [24]. The form (F) of varices was classified as
follows: straight small-calibred varices (F1); moderately
enlarged, beady varices (F2); or markedly enlarged, nodular,
or tumor-shaped varices (F3). Esophageal varices (F2) with
signs of impending bleeding, such as the red-color sign or
telangiectasia, and/ or those with form F3 were considered
large EV.
Portal hypertensive gastropathy was diagnosed by the
recognition of elementary lesions, such as a mosaic-like
pattern, red point lesions, cherry-red spots, or black-brown
spots [25].
Capsule endoscopy findings and scoring system
Capsule endoscopy was performed within one month after
performing EGD. A Pill Cam SB (Given Imaging, Yoqneam,
Israel) and RAPID system software version 5 were used.
The CE digital image stream was reviewed and interpreted
by two staff endoscopists blinded to the clinical and endo-
scopic information. Esophageal varices PHG (as detected by
CE) were not considered in this study.
Our scoring system of PHE depends on the classification
of the mucosal lesions of small bowel (SB) into four main
types; 1—red spots, 2—angioectasias, 3—SB varices, and
4—inflammatory-like lesions. The first three types comprised
the vascular lesions of PHE. Each of these four lesions was
worth two points if it was multiple (more than two lesions)
and only one point if it was not. We calculated the positive
points for every patient to make a final PHE score out of a
maximum of eight points.
Study Design
Data collected on each patient included age, sex, under-
lying hepatic pathology, liver function tests, blood count,
Child-Pugh class and grade, TE score, prior history of EIS
and/or EVL, and prior history of variceal bleeding.
We compared the prevalence and characteristics of SB
mucosal lesions between the cirrhotic and control patients.
Cirrhotic patients with and those without PHE were
compared to determine whether the PHE findings were
significantly associated with TE score and the other clinical
characteristics.
We explored the relationship between our scoring system
and the clinical outcome of the patients by studying the
statistical relationship between the PHE score and all the
clinical and endoscopic data of patients, including the TE
score.
Statistical analysis
The data is shown as mean ± SD. Comparisons were
performed using the student t test and the chi-square test.
Correlations between continuous data were done using
Pearson’s correlation. Differences were considered statisti-
cally significant when the p value was equal to or less than
0.05. Statistical analysis was performed using statistical
software (SPSS, version 16; SPSS Inc, Chicago, IL).
Results
During the study period, 31 cirrhotic patients with PHT
(19 females, and 12 males, mean age of all patients was
70.8 ± 8 years), and 29 control patients (9 females, and 20
males, mean age of all patients was 68.9 ± 11 years) were
enrolled in the study and were evaluated by CE. All patients
completed the CE procedure uneventfully. No complications
occurred, and the exit of the capsule was confirmed in all
the cases. The clinical, and endoscopic characteristics of
cirrhotic and control patients are listed in Table 1.
Transient elastography score was significantly different
between cirrhotic patients and control patients (p<0.001).
Capsule endoscopic findings
The mucosal findings detected by the CE in both cirrhotic
and control patients are listed in Table 1 (Figs. 1, 2).
Twenty-one of the cirrhotic patients (67.7%) were found to
have CE signs of PHE; nineteen patients (61.3%) of them
had diffuse PHE, and twenty patients (64.5%) had more
than one lesion. Active bleeding was seen during endoscopic
examination in only one case (3.2%) and was submitted to
double balloon endoscopy. On the other side, the mucosal
findings were present only in two of the control patients
(67.7% vs 6.9%, p<0.001). None of these patients revealed
diffuse lesions (61.3% vs 0, p<0.001), and none of them
had more than one lesion (64.5% vs 0, p<0.001).
The association between PHE and clinical characteristics of
the patients
A comparison of cirrhotic patients with and those without
PHE is shown in Table 2. Higher TE score (p =0 . 0 1 8 ) ,
high Child-Pugh score (p = 0.041), larger EV (p =0 . 0 2 3 ) ,
PHG (p = 0.049), and prior EIS/EVL (p = 0.023) were all
significantly associated with PHE. However, there was no
difference between these two groups of patients with regard
to hemoglobin level, hematocrit value, and prior history of
variceal bleeding.
The association between PHE score and clinical character-
istics of the patients
Using our scoring system, we sought to evaluate the
relationship between the score of PHE findings and the
clinical parameters in the cirrhotic patients to determineU.M. Abdelaal et al.
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whether the PHE score was associated with liver disease
severity (Child-Pugh score), and the endoscopic findings of
EGD (Table 3). As a result, we found that cirrhotic patients
with a high Child-Pugh score (p = 0.011), large EV
(p = 0.006), and prior EIS/EVL (p = 0.006) were signifi-
cantly associated with a higher PHE score (severe PHE).
Moreover, patients with a higher TE score were significantly
related with the PHE score (r = 0.561, p = 0.004) (Fig. 3).
Discussion
Liver cirrhosis is a progressive chronic liver disease, and
its clinical features are dependent on the disease duration
and the nature of the etiological factors [26]. Increased
resistance to portal blood flow due to liver cirrhosis leads
to PHT [27]. In fact, PHT results in the development of
gastroesophageal and/or ectopic (colonic, enteric) varices as
well as other mucosal lesions in the stomach, small intestine,
and colon [2, 28].
While portal hypertensive gastropathy and colonopathy
are considered as sources of non-variceal bleeding in
patients with liver cirrhosis and PHT, data on PHE is limited
[27]. The true prevalence and the clinical significance of
PHE are unknown. Likewise, the features of this condition
are not completely described because, in most instances, the
endoscopic diagnosis of PHE is impossible beyond the limit
of insertion of an enteroscope or the distal ileum (retrograde
ileoscopy).
Because CE examines the entire small bowel (SB), we
believed that it might reveal the mucosal changes and the
true extent of involvement of the small bowel in patients
with liver cirrhosis and PHT. This is important in view of
the enormous surface area of the SB and its inaccessibility
during routine gastrointestinal endoscopy and because the
study of the SB mucosa by enteroscopy is time consuming
and invasive [10].
In this study, the prevalence of SB mucosal lesions
compatible with PHE was significantly higher in cirrhotic
Table 1. Clinical, and endoscopic characteristics of cirrhotic and control patients
* p<0.05 was considered statistically significant. EIS, endoscopic injection sclerotherapthy; EVL, endoscopic
variceal ligation; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; TE, transient elastography; EGD,
esophagogastroduodenoscopy; EV, esophageal varices; PHG, portal hypertensive gastropathy; SB, small bowel;
NA, non applicable.
Characteristic
Cirrhotic Patients
 (n = 31)
Control Patients 
(n = 29)
p value
Prior variceal bleeding, n (%) 5 (16.1%) NA
Prior EIS/EVL, n (%) 8 (25.8%) NA
Underlying hepatic pathology, n (%):
HCV 8 (25.8%)
NA HCC 20 (64.5%)
Others 3 (9.7%)
Child-Pugh class, n (%):
A 20 (64.5%)
NA B 10 (32.3%)
C 1 (3.2%)
TE score, mean ± SD 26 ± 12.4 6.8 ± 1.4 <0.001*
EGD findings:
Esophageal varices, n (%)
Presence 26 (83.9%)
NA
Large EV 8 (25.8%)
Gastric varices, n (%) 16 (51.6%)
PHG, n (%) 20 (64.5%)
Capsule endoscopic findings:
Prevalence, n (%) 21 (67.7%) 2 (6.9%) <0.001*
SB mucosal lesions; n (%)
1—Red spots 17 (54.8%) 1 (3.4%) <0.001*
2—Angioectasias 16 (51.6%) 0 <0.001*
3—Inflammatory like lesions 13 (41.9%) 1 (3.4%) <0.001*
4—Varices 5 (16.1%) 0 0.024*Scoring System for PHE using CE
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Fig. 2. Capsule endoscopic views of the inflammatory lesions of portal hypertensive enteropathy. A: Erythema. B: Edematous villi.
Fig. 1. Capsule endoscopic views of the vascular lesions of portal hypertensive enteropathy. A: Red spot. B: Angioectasia. C: Serpigi-
nous small bowel varix.U.M. Abdelaal et al.
J. Clin. Biochem. Nutr.
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patients than in non-cirrhotic patients (67.7% vs 6.9%,
p<0.001). This prevalence of PHE among the cirrhotic
patient group was in accordance with that observed by
three previous similar studies [10,  27,  29]. Nevertheless,
presence of such lesions in non-cirrhotic patients (control
group) was a matter of conflict. Figueiredo et al. [29], and
Goulas et al. [27] revealed similar results to ours, but De
Palma et al. [10] revealed an absence of such lesions among
the non-cirrhotic patients.
The mucosal lesions of PHE included red spots with
highest percentage of presence (54.8%), followed by angio-
ectasias (51.6%), inflammatory-like lesions (41.9%), and
lastly SB varices (16.1%).
In our present study, a comparison of cirrhotic patients
with and without PHE revealed that cirrhotic patients with a
high TE score, worsening Child-Pugh class, larger EV, PHG,
and a prior history of EIS/EVL were significantly associated
with PHE. However, there was no difference between these
two groups of cirrhotic patients with regard to hemoglobin
level, haematocrit value, and prior history of variceal
bleeding. Our data was almost in accordance with those of
De Palma et al. [ 10], but it was not in accordance with
those of Figueiredo et al. [29] and Goulas et al. [27].
Currently, there is no scoring system for grading the
Table 2. Comparison of cirrhotic patients with and those without portal hypertensive enteropathy
* p<0.05 was considered statistically significant. PHE, portal hypertensive enteropathy; TE, transient
elastography; kPa, kilopascal; EV, esophageal varices; PHG, portal hypertensive gastropathy; EIS,
endoscopic injection sclerotherapthy; EVL, endoscopic variceal ligation.
Variable
with PHE 
(n = 21)
without PHE 
(n = 10)
p value
Laboratory findings; mean ± SD
Haemoglobin, g/dl 11.2 ± 2.1 11.1 ± 1.1 0.913
Haematocrit value, % 32.6 ± 5.3 29.4 ± 10.6 0.27
High Child-Pugh score, n (%) 10 (47.6%) 1 (10%) 0.041*
TE score, kPa; mean ± SD 29 ± 12.6 18 ± 7.8 0.018*
Endoscopic findings;
Large EV, n (%) 8 (38.1%) 0 (0%) 0.023*
Gastric varices, n (%) 11 (52.4%) 5 (50%) 0.901
PHG, n (%) 16 (76.2%) 4 (40%) 0.049*
Prior variceal bleeding, n (%) 5 (23.8%) 0 0.092
Prior EVL /EIS, n (%) 8 (38.1%) 0 0.023*
Table 3. The relation between PHE score and patients’ clinical variables
* p<0.05 was considered statistically significant. †Yes, presence of the variable; †No,
absence of the variable. PHE, portal hypertensive enteropathy; EV, esophageal varices;
PHG, portal hypertensive gastropathy; EIS, endoscopic injection sclerotherapthy;
EVL, endoscopic variceal ligation.
Variable PHE score mean ± SD p value
High Child Pugh score Yes† 3.4 ± 1.9
0.011*
No† 1.8 ± 1.6
Large EV Yes 3.7 ± 1.4
0.006*
No 1.7 ± 1.8
Gastric Varices Yes 2.1 ± 1.7
0.631
No 2.4 ± 2.1
PHG Yes 2.8 ± 1.6
0.289
No 1.7 ± 2.1
Prior EIS/EVL Yes 3.8 ± 1.4
0.006*
No 1.9 ± 1.8
Prior variceal bleeding Yes 3.4 ± 1.7
0.136
No 2 ± 1.9Scoring System for PHE using CE
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severity of mucosal abnormalities of PHE in cirrhotic
patients with PHT, making comparisons between studies
difficult. De Palma et al. [10] supposed that PHE lesions
detected by CE might be classified into two categories:
inflammatory-like lesions (edema, erythema, granularity,
friability) and vascular lesions (red spots, angioectasias,
and varices). Kodama et al. [30], in a study using double
balloon endoscopy, proposed that PHE lesions might be
classified into two categories: villous abnormalities and
vascular lesions. Then, Kodama et al. subclassified each
category into three further subcategories and gave one point
for every positive finding of these six subcategories. As a
result, a scoring system with a maximum of six points was
created. Nevertheless, his scoring system was not signifi-
cantly associated with any of the clinical variables of
patients, except for presence of ascites.
We proposed to make a scientifically reliable scoring
system using great modifications in that previous system,
and we statistically studied it with all variables of the
patients, especially TE score.
Our scoring system depends on the classification of the
mucosal lesions into main four lesions, as shown in Table 1:
inflammatory-like lesions and three vascular lesions, which
are red spots, angioectasisas, and SB varices. Each type of
these four lesions is worth two points if it was multiple
(more than two lesions) and one point if it was not. As a
result, the total score was eight points maximally. In our
scoring system, we aimed to give greater attention to the
vascular lesions more than inflammatory ones, as they seem
to be the most important lesions clinically, which might be
sources for overt or occult bleeding. Moreover, bleeding
vascular lesions can be treated endoscopically with injection
sclerotherapy for varices and argon plasma coagulation for
angioectasisas or red spots.
Cirrhotic patients with a high Child-Pugh score (p =
0.011), large EV (p = 0.006), and prior EIS/EVL (p = 0.006)
were significantly associated with a higher PHE score.
Moreover, we found that patients with a higher TE score
were significantly related with the PHE score (p =0 . 0 0 4 ) .
As a result, we thought that our scoring system might have a
prognostic value, because it was significantly associated
with parameters of liver disease severity (Child-Pugh score),
and PHT (EV, TE score, and prior EIS/EVL).
Capsule endoscopy has a useful role in detection of
mucosal lesions of PHE, and in assessment of its severity
(PHE score). Nevertheless, CE is an expensive investiga-
tion, which could not be used daily for cirrhotic patients.
We proposed that TE had an important clinical impact in
such field, because using TE as a non-invasive and cheap
maneuver could be helpful to suspect the presence and
severity of PHE, especially if these patients have bleeding
and conventional endoscopy was negative.
In conclusion, the mucosal changes compatible with PHE
are significantly more common in cirrhotic patients than in
non-cirrhotic patients. Higher PHE score was related to the
degree of liver disease, and portal hypertension. Transient
elastography might be a new non-invasive method that can
be used in detection of mucosal lesions of PHE. The exact
clinical significance of PHE remains unknown. In the future,
further large-scale studies using our scoring system are
required to declare the significance of PHE, and to deter-
mine a LSM cutoff value using transient elastography for
best prediction of PHE.
Abbreviations
PHT, portal hypertensive enteropathy; PHG, portal hyper-
tensive gastropathy; EV, esophageal varices; EGD, esophago-
gastroduodenoscopy; CE, capsule endoscopy; HVPG, hepatic
venous pressure gradient; TE, transient elastography; kPa,
kilopascal; LSM, liver stiffness measurement; EIS, endo-
scopic injection sclerotherapy; EVL, endoscopic variceal
ligation; SB, small bowel.
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